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Parkinson’s disease (PD) is characterized by
degeneration ofmesodiencephalic dopami-
nergic neurons (mdDAns). Importantly,
the disease primarily affects mdDAns of the
substantia nigra pars compacta (SNc), leav-
ing mdDAns in the ventral tegmental area
(VTA) relatively unaffected (Brichta and
Greengard, 2014). A prospective treatment
involves replacement of degenerated
mdDAns with neurons derived from plu-
ripotent stem cells (PSCs), and many neu-
rodevelopmental studies have focused on
the establishment of effective cell replace-
ment strategies (Steinbeck and Studer,
2015). Because the PSC-derived neurons of
the SNc subtype (as opposed to those of the
VTA subtype) are critical for recovery and
proper innervation in PD models upon
grafting (Thompson et al., 2005; Grealish et
al., 2010), selective generation of PSC-
derived SNc-mdDAns is necessary. Efforts
to achieve this long-standing goal have been
hampered by incomplete understanding of
themolecular profiles andprogramsunder-
lying the generation of SNc- and VTA-
mdDAns in vivo. Nonetheless, some recent
studies have partially unveiled howmdDAn
subset-specification is established (Veenv-
liet and Smidt, 2014; Bodea and Blaess,
2015), but the possibility of using this
knowledge to increase the yield of PSC-
derived SNc-mdDAns has only begun to be
exploited. In their recent study,Fukusumiet
al. (2015) not only identify a secreted factor,
Dickkopf 3 (Dkk3), that specifically pro-
motes the differentiation of SNc-mdDAns
in vivo, but also use this information to de-
velop a protocol that increases the fraction
of SNc-like mdDAns derived from PSCs.
SNc- and VTA-mdDAns arise from
proliferating progenitors in the ventricu-
lar zone of the mesodiencephalic floor
plate. These progenitors express the mor-
phogenetic factor WNT1 (Brown et al.,
2011), which is essential for progenitor
proliferation: WNT1 knock-out mice dis-
play complete absence or severe depletion
of mdDAns (Wurst and Prakash, 2014).
The effect of WNT1 on progenitor prolif-
eration is mediated by stimulation of the
canonical WNT/-catenin pathway (Jok-
simovic and Awatramani, 2014). Later in
development,mdDAndifferentiation and
maturation proceeds upon shifting the
balance from canonical to noncanonical
WNT signaling (Arenas, 2014). WNT sig-
naling is modulated by Dickkopfs.
Whereas DKK1/2/4 potently inhibit ca-
nonical WNT signaling by binding to
LRP5/6, DKK3 does not bind LRP at the
cell membrane, and the directionality of
its effect on WNT signaling and the un-
derlying mechanism are largely unclear
(Veeck and Dahl, 2012).
Fukusumi et al. (2015) demonstrated
that in the mdDA area, Dkk3 is first de-
tected at embryonic day (E) 11.5. In
Dkk3/ embryos, PITX3, that is nor-
mally expressed in developingmdDAns of
both the SNc and VTA subtypes, is not
induced in a rostrolateral subset of TH
neurons around E14.5 (TH is the rate-
limiting enzyme for dopamine synthesis),
when the total number of THmdDAns
is still unaffected. Importantly, mdDAns
positioned rostrolaterally at E14.5 mainly
contribute to the adult SNc, whereas
caudomedial-located mdDAns mainly
give rise to the VTA (Veenvliet and Smidt,
2014). This programming defect ulti-
mately leads to a decreased number of
SNc-mdDAns, but not VTA-mdDAns,
from E18.5 onwards. Therefore, the in
vivo data suggest that DKK3 is critical for
the induction of PITX3 in developing
SNc-mdDAns, and that a failure to do so
in the absence ofDKK3ultimately leads to
their specific degeneration. These data
demonstrate the importance of careful
spatiotemporal analysis of the mdDA sys-
tem in mutant embryos using combina-
tions of multiple mdDA markers in
neuro-anatomically defined regions of in-
terest: without the assessment of different
subpopulations, the earlier defects in
Dkk3/ embryos would have gone un-
noticed, because total TH cell numbers
were not affected at E14.5.
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The specific and exclusive generation of
SNc-mdDAns is the holy grail of regenera-
tive medicine, and the identification of
compounds that increase SNc-mdDAn
yield in vitro would be seminal. It is there-
fore of utmost interest that Fukusumi et al.
(2015) continued to demonstrate that in
vitro, treatmentwithWNT1,DKK3,orboth
not only increased the percentage of TH/
PITX3 PSC-derived mdDAns, but that
this was accompanied by an increased
percentage of KCND3/TH cells with a
concomitant decrease of CALB1/TH
mdDAns, indicative of a WNT1/DKK3-
mediated induction of the rostrolateral SNc
fate at the expense of the caudomedial VTA
fate indifferentiatingPSCs (Fukusumi et al.,
2015, their Fig. 8). Because PITX3 is widely
expressed in all skeletal muscles of the body
(L’Honore´ et al., 2007), andDKK3has a de-
cisive function in subtype specification of
myogenic cells (Veeck andDahl, 2012), it is
an intriguing possibility that such DKK3-
mediated subset-specification of cells that
display PITX3 expression is a conserved
phenomenon.
Surprisingly, the effects of DKK3 loss
in vivo were similar to the effect of DKK3
treatment in vitro: whereas in vitro
WNT1/DKK3 treatment subtly increased
the percentage of PSC-derived putative
SNc-mdDAns at the expense of CALB1/
TH mdDAns (mainly of the VTA sub-
type),Dkk3/mice displayed amarginal
decrease of CALB1/THmdDAns (Fu-
kusumi et al., 2015, their Fig. 8H–N).
How can this be explained? A hallmark
study demonstrated that strong activation
of canonical Wnt signaling [using GSK3
inhibitorCHI99021 (CHIR)] is critical for
obtaining bona fidePSC-derivedmdDAns
(Kriks et al., 2011). It is therefore evident
that, in contrast to the wild-typemdDAns
taken as a control in vivo, cells in the con-
trol condition for the in vitro experiments
(omission of WNT1/DKK3) are not bona
fide mdDAns. When WNT1 or CHIR
treatment is regarded as a control, DKK3
has no additional effect in increasing SNc-
mdDAn yield (Fukusumi et al., 2015, their
Fig. 8G). However, like sole treatment
with WNT1, treatment with DKK3 alone
shifted the balance to SNc-mdDAns, and
may therefore offer another way of in-
creasing SNc-mdDAn yield from PSCs.
Whether this is truly an alternative path-
way should be elucidated in future studies
by unraveling regulatory networks under-
lying DKK3 (as compared with WNT1)
function in mdDAn development.
Such lack of detailed analysis of path-
ways conducting the observed effects is a
general limitation of the study: although the
phenotypical effects of DKK3 loss- or gain-
of-function are of utmost interest, the exact
underlying mechanisms remain unre-
solved, and it remains unclear whether
WNT1 and DKK3 increased mdDAn yield
via similar or differentmechanisms. For ex-
ample,WNT1may act by increasingmdDA
progenitor proliferation, whereas DKK3
could affect mdDAn maturation, both
eventually resulting in a higher mdDAn
yield. Detailed comparative transcriptome
analysis of all in vitro treatment conditions
could resolve this issue. Fukusumi et al.
(2015) demonstrated the power of such
analysis by comparative global expression
profiling of FACS-purified in vitro and in
vivo differentiated PITX3-GFPmdDAns,
thereby confirming the findings of a recent
study that revealed an aberrant transcrip-
tome of induced PSC-derived mdDAns
compared with their in vivo counterpart
(Roessler et al., 2014). However, whereas
comparative transcriptome analysis of all in
vitro differentiation conditions would have
Figure1. Experimental pipeline for the identification of factors essential for SNc development in vivo and the systematic study of their potential in stem cell therapy for Parkinson’s disease. Novel
SNc-specific factors can be identified by global expression analysis of mdDAn subsets. Since no specific reporter lines exist to purify developing SNc neurons, these factors can be identified based on
transcriptome analysis after anatomical separation, by single-cell RNA-Seq ofmdDAns, and/or by analysis of mutants that display SNc-specific degeneration. Novel putativemarkers can be used to
generate reporter lines,which in turn canbeused to explore the SNc-specific transcriptome inmore detail. In thenext phase, putative subset-specific factors, preferably secreted factors for their easy
application and therapeutic potential, should be tested for their ability to protect against SNc-mdDAndegeneration in vitro (e.g., in ventralmidbrain primary cultures ofmutantmice), aswell as their
ability to increase SNc-mdDAn yield from PSCs in vitro. An appropriate control condition for such an experiment would consist of a standard protocol that generates bona fide mdDAns. It may be
critical to test different dosages, combinations, and timing schemes,whichwill require a high-throughput experimental system. This can be achieved by the use of reporter lines carrying fluorescent
proteins under the control of an SNc-specific marker, in combination with a pan-specific mdDAn marker (e.g., PITX3-GFP), which can be used in combination with FACS to assess both mdDAn
differentiation efficiency and shifts in SNc/VTA-mdDAn ratio. Finally, behavioral recovery in animal models of PD upon grafting of PSC-derived SNc-mdDAns needs to be demonstrated, and
PSC-derived SNc-mdDAns should be compared with their in vivo counterpart in terms of their physiology, epigenome, and transcriptome to assess that they are bona fide SNc-mdDAns.
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been highly informative, the authors only
studied the effects of combinatorialWNT1/
DKK3 treatment as compared with their
omission.Although they found somediffer-
ences, this analysis onlyprovided limited in-
sight into the pathways that conduct the
treatment effect (Fukusumi et al., 2015,
theirFig. 7B,C).A likely explanation for this
is that analysis was performed on FACS-
purified PITX3-GFPmdDAns. This lim-
ited the transcriptome analysis of the
untreated control cells to thosePSC-derived
mdDAns in which PITX3 is induced inde-
pendently of DKK3/WNT1 by effectively
removing PITX3/TH mdDAns from
the analysis. However, because DKK3 in-
duces PITX3 expression in a SNc subset of
THmdDAns, itwouldhavebeenessential
to include both PITX3/TH and
PITX3/TH cells in the analysis toobtain
insight into how DKK3/WNT1 induces
PITX3 in TH SNc-mdDAns. Analysis of
all TH cells, independent of their PITX3
expression (for example by FACS-
purification of mdDAns based on a TH re-
porter) would therefore have been more
informative.
The authors’ transcriptome analysis
also demonstrated something else they
did not discuss: in vitro samples primarily
clustered according to the independent
differentiation experiments, but not the
treatment condition within those experi-
ments, suggesting that experimental vari-
ance is a more important predictor of the
differentiation outcome than the experi-
mental treatment (Fukusumi et al., 2015,
their Fig. 7D). Importantly, in one of the
differentiation experiments (Con3/5_19
in their Fig. 7E), mdDAns were obtained
that expressed mdDAn markers at levels
more comparable to those of mdDAns in
vivo, including high levels of rostrolateral
mdDAn markers (Veenvliet and Smidt,
2014). These findings suggest that there
are many variables besides the treatment
condition (e.g., plating density, timing of
treatments, passage number of starting
culture) that influence the final resem-
blance of PSC-derivedmdDAns to their in
vivo counterpart, and it is important to
analyze the effect of these conditions on
the differentiation outcome.
Despite these caveats, the identifica-
tion of a WNT modulator as a novel
regulator ofmdDAndevelopment is of ut-
most interest, because fine-tuning of
WNT cascades is critical for inducing the
proper molecular signature of mdDAns
and may influence mdDAn subtype (Are-
nas, 2014). For example, excess WNT/-
catenin signaling leads to improper
progenitor specification, and SNcprogen-
itors may be more susceptible to this
(Nouri et al., 2015). In this light, DKK3
may act by fine-tuning the WNT signal
and/or modulating the balance between
canonical and noncanonical WNT signal-
ing, thereby facilitating differentiation of
progenitors toward SNc-mdDAns, while
suppressing other fates. If this is the case,
it follows that sequential application of
WNT1 and DKK3 could be beneficial,
first triggering WNT1-induced mdDA
progenitor expansion followed by DKK3-
induced mdDAn differentiation. This
should be tested in future studies, to-
gether with careful dosage titration.
Finally, the study is of critical impor-
tance to the field because of its experimen-
tal pipeline, which should be further
expanded in future studies (Fig. 1). Due to
the ever-increasing feasibility of identify-
ing and characterizing small, defined sub-
sets of cells in vivo, it is not a question of if,
but rather how many subset-specific fac-
tors will be identified. Against this back-
ground, the authors’ approach excellently
demonstrates how initial clues from
explorative neurodevelopmental studies
should be used to develop differentiation
protocols that efficiently and specifically
generate SNc-mdDAns from PSCs.
In sum, the study by Fukusumi et al.
(2015) emphasizes the necessity of study-
ing mdDAn development in normal and
mutant mice, and demonstrates how the
systematic study of factors essential for in
vivo SNc development can ultimately pro-
vide us with the proper recipe for safe
stem cell therapy in PD.
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